Trial · NCT01691898
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 63 | |
| Overall Study | STARTED | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 59 | |
| Overall Study | STARTED | Cohort C (FL): RTX + Polatuzumab | 20 | |
| Overall Study | STARTED | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | 9 | |
| Overall Study | STARTED | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | 40 | |
| Overall Study | STARTED | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab | 40 | |
| Overall Study | COMPLETED | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 16 | |
| Overall Study | COMPLETED | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 15 | |
| Overall Study | COMPLETED | Cohort C (FL): RTX + Polatuzumab | 11 | |
| Overall Study | COMPLETED | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | 4 | |
| Overall Study | COMPLETED | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | 26 | |
| Overall Study | COMPLETED | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab | 5 | |
| Overall Study | NOT COMPLETED | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 47 | |
| Overall Study | NOT COMPLETED | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 44 | |
| Overall Study | NOT COMPLETED | Cohort C (FL): RTX + Polatuzumab | 9 | |
| Overall Study | NOT COMPLETED | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | 5 | |
| Overall Study | NOT COMPLETED | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | 14 | |
| Overall Study | NOT COMPLETED | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab | 35 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01691898/flow